Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05893420 · ClinicalTrials.gov registry record · NA
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
A NA study of COVID-19 and Sepsis, sponsored by AgileMD.
- Active
- Registry status
- NA
- Development phase
- 30,000
- Enrollment target
- 3
- Study locations
NCT05893420: Active NA study of COVID-19 and Sepsis, sponsored by AgileMD.
NCT05893420 is a NA study of COVID-19 and Sepsis that is active but no longer recruiting, run by AgileMD. The registered enrollment target is 30,000 participants, below the 38,364-participant average among 298 other COVID-19 trials with a reported enrollment target (22% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05893420, a NA study of COVID-19 and Sepsis, is active but no longer recruiting, sponsored by AgileMD.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients. The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.
Primary Outcome
Hospital mortality, a measure of how many patients died in the hospital, will come from administrative data, specifically from the discharge disposition of each eCART elevated risk patient. This data will be taken from the complete hospitalization, from admission to discharge.
Conditions Studied
Interventions
- OTHER Standard of care control
- DEVICE eCARTv5 clinical deterioration monitoring
Study Locations (3)
Connecticut
- Yale New Haven Health System - New Haven
Florida
- BayCare Health System - Clearwater
Wisconsin
- University of Wisconsin Health - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2024-12-31 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT05893420 still lists
NCT05893420 is an interventional study that assigns participants to a tested intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,364-participant average among 298 other COVID-19 trials with a reported enrollment target (22% lower).
The record links to 7 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Standard of care control is the first listed.
NCT05893420 reports a single indexed study location in Connecticut, Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05893420 about?
NCT05893420 is a clinical study titled "A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning". In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which pa...
What is the current status of trial NCT05893420?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30,000 participants. The study started on 2024-12-31. Estimated completion is 2026-12-31.
What conditions does trial NCT05893420 study?
This clinical trial studies the following conditions: COVID-19, Sepsis, Respiratory Failure, Cardiac Arrest, Hemodynamic Instability.
What interventions are being tested in trial NCT05893420?
The interventions under investigation include: Standard of care control (OTHER), eCARTv5 clinical deterioration monitoring (DEVICE).
Who is sponsoring clinical trial NCT05893420?
This trial is sponsored by AgileMD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05893420 being conducted?
This trial has 3 study locations across Connecticut, Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05893420's enrollment target sits among peer trials
30,000 12th of 298 higher than 287 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI